S&P 500   4,278.79 (-0.61%)
DOW   34,009.30 (-0.42%)
QQQ   328.96 (-1.00%)
AAPL   174.62 (+0.92%)
MSFT   291.29 (-0.49%)
META   175.49 (-2.22%)
GOOGL   119.93 (-1.45%)
AMZN   142.21 (-1.78%)
TSLA   909.93 (-1.06%)
NVDA   183.47 (-2.82%)
NIO   20.17 (-3.54%)
BABA   90.06 (-2.80%)
AMD   98.14 (-2.06%)
MU   61.57 (-3.59%)
T   18.43 (-0.75%)
CGC   4.07 (+7.67%)
F   16.08 (-2.13%)
GE   79.84 (-1.52%)
DIS   123.10 (-1.49%)
AMC   22.12 (-10.84%)
PYPL   99.60 (-2.43%)
PFE   49.36 (-1.00%)
NFLX   240.69 (-2.04%)
S&P 500   4,278.79 (-0.61%)
DOW   34,009.30 (-0.42%)
QQQ   328.96 (-1.00%)
AAPL   174.62 (+0.92%)
MSFT   291.29 (-0.49%)
META   175.49 (-2.22%)
GOOGL   119.93 (-1.45%)
AMZN   142.21 (-1.78%)
TSLA   909.93 (-1.06%)
NVDA   183.47 (-2.82%)
NIO   20.17 (-3.54%)
BABA   90.06 (-2.80%)
AMD   98.14 (-2.06%)
MU   61.57 (-3.59%)
T   18.43 (-0.75%)
CGC   4.07 (+7.67%)
F   16.08 (-2.13%)
GE   79.84 (-1.52%)
DIS   123.10 (-1.49%)
AMC   22.12 (-10.84%)
PYPL   99.60 (-2.43%)
PFE   49.36 (-1.00%)
NFLX   240.69 (-2.04%)
S&P 500   4,278.79 (-0.61%)
DOW   34,009.30 (-0.42%)
QQQ   328.96 (-1.00%)
AAPL   174.62 (+0.92%)
MSFT   291.29 (-0.49%)
META   175.49 (-2.22%)
GOOGL   119.93 (-1.45%)
AMZN   142.21 (-1.78%)
TSLA   909.93 (-1.06%)
NVDA   183.47 (-2.82%)
NIO   20.17 (-3.54%)
BABA   90.06 (-2.80%)
AMD   98.14 (-2.06%)
MU   61.57 (-3.59%)
T   18.43 (-0.75%)
CGC   4.07 (+7.67%)
F   16.08 (-2.13%)
GE   79.84 (-1.52%)
DIS   123.10 (-1.49%)
AMC   22.12 (-10.84%)
PYPL   99.60 (-2.43%)
PFE   49.36 (-1.00%)
NFLX   240.69 (-2.04%)
S&P 500   4,278.79 (-0.61%)
DOW   34,009.30 (-0.42%)
QQQ   328.96 (-1.00%)
AAPL   174.62 (+0.92%)
MSFT   291.29 (-0.49%)
META   175.49 (-2.22%)
GOOGL   119.93 (-1.45%)
AMZN   142.21 (-1.78%)
TSLA   909.93 (-1.06%)
NVDA   183.47 (-2.82%)
NIO   20.17 (-3.54%)
BABA   90.06 (-2.80%)
AMD   98.14 (-2.06%)
MU   61.57 (-3.59%)
T   18.43 (-0.75%)
CGC   4.07 (+7.67%)
F   16.08 (-2.13%)
GE   79.84 (-1.52%)
DIS   123.10 (-1.49%)
AMC   22.12 (-10.84%)
PYPL   99.60 (-2.43%)
PFE   49.36 (-1.00%)
NFLX   240.69 (-2.04%)
NASDAQ:NK

NantKwest - NK Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$4.36
$4.76
50-Day Range
$16.09
$38.70
52-Week Range
$2.52
$45.42
Volume
1.22 million shs
Average Volume
1.57 million shs
Market Capitalization
$497.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
NK stock logo

About NantKwest (NASDAQ:NK) Stock

NantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's N-801 and/or N-803 products; collaboration with Be The Match BioTherapies for the development of cell therapy to prevent COVID-19 deaths; and strategic alliance with Immunitybio. It also has a collaboration with CBR Systems, Inc. to develop a COVID-19 treatment leveraging newborn stem cells. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.

Receive NK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NantKwest and its competitors with MarketBeat's FREE daily newsletter.

NK Stock News Headlines

How High Can Copper Go?
To power the green revolution, copper demand continues to skyrocket with no end in sight. Prices hit a 10-year high; as copper jumped 79% in the past year. Some analysts are calling for copper to rise another 50-100%! We may be at the beginning of a copper bull run the likes we've never seen before. Just how high can copper go?
How High Can Copper Go?
To power the green revolution, copper demand continues to skyrocket with no end in sight. Prices hit a 10-year high; as copper jumped 79% in the past year. Some analysts are calling for copper to rise another 50-100%! We may be at the beginning of a copper bull run the likes we've never seen before. Just how high can copper go?
See More Headlines

Receive NK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NantKwest and its competitors with MarketBeat's FREE daily newsletter.

NK Company Calendar

Last Earnings
5/11/2020
Today
8/17/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
160
Year Founded
N/A

Profitability

Net Income
$-65,790,000.00
Net Margins
-76,658.58%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$40,000.00
Price / Sales
12,437.99
Book Value
$1.23 per share

Miscellaneous

Free Float
N/A
Market Cap
$497.52 million
Optionable
Optionable
Beta
2.61

Key Executives

  • Dr. Barry J. Simon (Age 56)
    Pres, Chief Admin. Officer & Exec. Director
    Comp: $454.44k
  • Ms. Sonja Nelson (Age 48)
    Chief Financial Officer
    Comp: $442.69k
  • Mr. Richard Gerald Adcock (Age 52)
    Chief Exec. Officer
  • Mr. Steven Yang J.D.
    VP, Gen. Counsel & Corp. Sec.
  • Dr. Jerel A. Banks Ph.D. (Age 46)
    M.D., Sr. VP Mergers and Acquisitions
  • Mr. Leonard S. Sender
    Sr. VP of Medical Affairs - Pediatric, Adolescent & Young Adult Oncology
  • Dr. Hans Georg Klingemann (Age 71)
    VP of R&D













NK Stock - Frequently Asked Questions

How were NantKwest's earnings last quarter?

NantKwest, Inc. (NASDAQ:NK) released its quarterly earnings data on Monday, May, 11th. The biotechnology company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.17) by $0.02. The biotechnology company earned $0.02 million during the quarter. NantKwest had a negative net margin of 76,658.58% and a negative trailing twelve-month return on equity of 56.06%.

What is Dr. Patrick Soon-Shiong's approval rating as NantKwest's CEO?

14 employees have rated NantKwest Chief Executive Officer Dr. Patrick Soon-Shiong on Glassdoor.com. Dr. Patrick Soon-Shiong has an approval rating of 55% among the company's employees. This puts Dr. Patrick Soon-Shiong in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of NantKwest own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NantKwest investors own include Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), OPKO Health (OPK), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Trevena (TRVN) and ADMA Biologics (ADMA).

When did NantKwest IPO?

(NK) raised $150 million in an IPO on Tuesday, July 28th 2015. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. BofA Merrill Lynch, Citigroup, Jefferies and Piper Jaffray served as the underwriters for the IPO and MLV & Co. was co-manager.

What is NantKwest's stock symbol?

NantKwest trades on the NASDAQ under the ticker symbol "NK."

What is NantKwest's stock price today?

One share of NK stock can currently be purchased for approximately $4.55.

How much money does NantKwest make?

NantKwest (NASDAQ:NK) has a market capitalization of $497.52 million and generates $40,000.00 in revenue each year. The biotechnology company earns $-65,790,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis.

How many employees does NantKwest have?

The company employs 160 workers across the globe.

How can I contact NantKwest?

NantKwest's mailing address is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. The official website for the company is www.nantkwest.com. The biotechnology company can be reached via phone at 858-633-0300 or via email at investors@nantkwest.com.

This page (NASDAQ:NK) was last updated on 8/17/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.